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subtypeBackground/Purpose: The decoy receptor 3 (DcR3) is a member of the tumor necrosis factor
receptor (TNFR) super-family. It counteracts the biological effects of Fas ligands and inhibits
apoptosis. The goals of this study were to understand the associations between serologic
DcR3 (sDcR3) levels and different human immunodeficiency virus type 1 (HIV-1) subtypes, as
well as the AIDS disease progression.
Methods: Serum samples from 61 HIV/AIDS patients, who had been followed up every 6 months
for 3 years, were collected. sDcR3 levels were quantified using an enzyme immunoassay (EIA).
Results: The sDcR3 levels in patients with HIV-1 subtype B were significantly higher than those
in patients infected with subtype CRF01_AE (p < 0.001). In addition, multivariable linear mixed
model analysis demonstrated that HIV-1 subtype B and slow disease progression were associ-
ated with higher levels of sDcR3, adjusting for potential predictors (p Z 0.0008 and 0.0455,
respectively).
Conclusion: HIV-1-infected cells may gain a survival advantage by activating DcR3, which pre-
vents infected cell detection by the host immune system. These data indicate that the sDcR3
level is a biomarker for AIDS disease progression.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
patients 499Introduction
The human immunodeficiency virus type 1 (HIV-1) causes
AIDS and is one of the leading causes of mortality world-
wide.1,2 HIV-1-infected individuals have revealed that
gradual CD4þ T cell depletion takes place in mucosal tis-
sues and peripheral blood during chronic infection.3e5
Apoptosis is thought to occur in HIV-infected individuals
and may arise from mechanisms including HIV-induced
syncytium formation, HIV protein-induced cell death,
activation-induced cell death, and bystander cell killing.6e9
The course of HIV infection varies widely among individuals.
The median time from infection to development of AIDS is
8e10 years, but a small proportion of patients, probably no
more than 5e10%, have been characterized as long-term
nonprogressors.10,11 In contrast, perhaps 10% of all HIV-
infected persons are rapid progressors, who develop AIDS
within 5 years of infection with HIV.12,13 The course of HIV
infection varies widely among individuals. The interaction
of numerous viral and host factors, such as viral virulence,
host genetics, host immune response, and cytokine milieu,
is believed to determine the course of disease.
Members of the tumor necrosis factor receptor (TNFR)
superfamily mediate pleiotropic biological processes, such
as cell proliferation, differentiation, apoptosis and cyto-
kine production. DcR3, also known as TR6 or M68, is a new
secreted member of the TNFR superfamily and can block
the cellular effects by binding to ligands of the TNF family,
including Fas ligand (FasL), LIGHT, and TNF-like molecule
1A (TL1A).14e16 FasL induces apoptosis in target cells
through the death receptor Fas and it is reported that DcR3
can prevent FasL-mediated apoptosis.14,17 Overexpression
of DcR3 has been reported in many cancers,18e21 and sys-
temic lupus erythematous (SLE) patients,22 and is associ-
ated with poor prognoses.23 A recent study demonstrates
that DcR3 expression might be a prognostic marker in
various cancers.23e25 Furthermore, the elevated levels of
soluble DcR3 in the sera of patients with gastric, liver, and
gallbladder carcinomas, bacterial infection and renal fail-
ure, have also been reported.26e28 Therefore, it issuggested that DcR3 may produce a relative advantage for
tumor growth and survival. In animal models, DcR3 is shown
to be effective at attenuating FasL-induced mortality
and acute pulmonary inflammation.29,30 Transgenic over-
expression of DcR3 is also shown to play a protective role in
a rodent diabetic model.31 DcR3 is also reported to modu-
late a variety of immune responses. Infiltration of CD4þ and
CD8þ T cells, as well as microglia/macrophages, into gli-
omas, is suppressed by DcR3.21 When human T cells are
pretreated with DcR3, it is found that T cell chemotaxis is
inhibited in vitro and in vivo.32 Recombinant DcR3 is also
shown to downregulate cytotoxic T lymphocyte (CTL) ac-
tivities to alloantigens and to modulate lymphokine pro-
duction.33 Additionally, exogenous DcR3 was reported to
modulate dendritic cells (DCs) differentiation and matura-
tion from CD14þ monocytes and these skewed naı¨ve T cells
toward a T helper cell type 2 (Th2) phenotype.34 This sug-
gests that DcR3 might have potent, suppressive effects in
downregulation of the host immune system. All the evi-
dence suggested the possibility that DcR3 might be one of
the factors responsible for the progression and immune
evasion of cancer cells.
Materials and methods
Participants
We used specimens and data from the AIDS Prevention and
Research Centre, National Yang-Ming University to investi-
gate the associations between sDcR3 and different HIV-1
subtypes, as well as the AIDS disease progression. A total of
61 HIV-1-infected patients who provided 686 serum sam-
ples, with 4e17 visits/patient, were enrolled in this follow-
up study from 2000 through 2002. Among 61 HIV-1 infected
patients, 50 (82%) were male and the median age was 36
years (rangeZ 19e60 years). In addition, all of the patients
were receiving antiretroviral therapy. For each HIV-1 pa-
tient included in this study, the day of diagnosis was
considered as time zero of the analysis. After the date of
diagnosis, HIV-1 patients whose CD4þ T lymphocyte counts
500 Y.-T. Lin et al.quickly decreased to <200 cells/mL within 3 years, were
termed fast progressors. HIV-1 patients whose CD4þ T
lymphocyte counts remained at >200 cells/mL within
3 years after the date of diagnosis and declined gradually
after 3 years, were termed typical progressors. From the
date of diagnosis to 2003, HIV-1 patients whose CD4þ T
lymphocyte counts maintained at >500 cells/mL were
termed slow progressors. HIV-1 subtypes were determined
using polymerase chain reaction (PCR) and phylogenetic
analysis.35 In addition, 145 normal adults who had under-
gone a physical examination from Kaohsiung Yuan’s General
Hospital and the Renai branch of Taipei City Hospital, were
recruited from 2000 to 2004. All of the normal controls
were HIV-1 seronegative. Adults with abnormal GOT and
GPT levels (>40 U/L), abnormal platelet levels
(>400  103/mL), abnormal carcinoembryonic antigen
(CEA) levels (>4 ng/mL), or HBV and HCV infection, were
excluded from the control group. Men with abnormal re-
sults of clinical prostate examination and women with
abnormal results of clinical breast examination, or cervical
smear tests, were also excluded from the control group.
Informed consent was obtained from all participants in this
study and the study was approved by the Institutional Re-
view Board of the National Yang-Ming University.
Serological testing
To measure sDcR3 in HIV-infected patients and the control
group, sandwich ELISA was used, containing 9A10C3 and
3H5 monoclonal antibodies. Briefly, each sample was
incubated in duplicate in microplates coated with 9A10C3
overnight. Following incubation, the biotin-conjugate 3H5
monoclonal antibody was added and incubated as a primary
antibody for 2 hours. After the microplate had been
washed, streptavidin-alkaline phosphatase (SA-AKP) (Sigma
Co., St. Louis, MO) was added and incubated for 2 hours.
After washing off any unbound SA-AKP, p-nitrophenyl
phosphate (pNPP) (Sigma) was added as a substrate, andTable 1 Characteristics of HIV-1-infected patients and normal
HIV-1 infecte
Male (%) (n Z 50) Female (%)
Age (y)
<30 17 (34.0) 9 (81.8)
30e39 17 (34.0) 1 (9.1)
40e49 12 (24.0) 1 (9.1)
>50 4 (8.0) 0 (0)
Median þ SE (range) 33  1.5 (19e60) 24  2.0 (1
Subtype
Subtype B 39 (78.0) 4 (36.4)
CRF01_AE 11 (22.0) 7 (63.6)
Progressors
Fast progressor 21 (42.0) 2 (18.2)
Typical progressor 19 (38.0) 6 (54.5)
Slow progressor 10 (20.0) 3 (27.3)
CD4 (cells/mm3) 400  13.0 540  30.4
CD8 (cells/mm3) 955  20.5 845  39.3
Viral load 0.5  6.2 0.5  41.5the absorbance was measured at 405 nm after 20 minutes
with an ELISA reader. The absorbance of each sample was
plotted against a standard curve produced by serial di-
lutions of recombinant DcR3 protein. The amount of DcR3 in
the serum samples was determined by extrapolation using
calibration curves. The sensitivity limit of the ELISA was
1 ng/mL. All samples with an absorbance of less than the
average of the negative control plus two standard de-
viations (SD), were considered as nondetectable.
Statistical analysis
Univariate analysis was performed using either the Pearson
c2 test or the Fisher’s exact test, as appropriate in
comparing the proportions of HIV-1-seropositive subtypes
between males and females. Mann-Whitney-Wilcoxon
(MWW) Test was used to compare the virus-associated
factors, physiological values, and sDcR3 concentrations
between male and female individuals from the HIV-1-
seropositive groups. The Kruskal-Wallis One Way Test was
conducted to compare the sDcR3 concentrations between
different disease progressors. A multivariable linear mixed
model was performed to identify factors associated with
higher levels of sDcR3. SAS statistic software (SAS version
9.1; SAS Institute, Cary, NC, USA) was used for all analyses.
Statistical significance was set at p < 0.05.Results
Characteristics of HIV-1-infected patients and
normal controls
The characteristics of the HIV-1-infected patients and
control group included in this study are shown in Table 1.
Among HIV-1-infected patients, the age of males (n Z 50;
33  1.5 years) was significantly higher than that of females
(n Z 11; 24  2.0 years) (MWW Test, p Z 0.003). Thecontrols included in the study.
d population Normal
(n Z 11) Total (%) (n Z 61) Total (%) (n Z 145)
26 (42.6) 26 (17.9)
18 (29.5) 69 (47.6)
13 (21.3) 49 (33.8)
4 (6.6) 1 (0.7)
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Figure 1 Serologic decoy receptor 3 (sDcR3) in HIV-1-
infected patients. Serum samples of HIV-1 patients in multi-
ple time points and normal controls were obtained and sDcR3
were assayed by ELISA in duplicate: (A) sDcR3 of 61 HIV-1-
infected patients (50 male and 11 female) and 145 normal
controls (100 male and 45 female) were measured; (B) sDcR3 of
HIV-1 patients infected with subtype B (gray triangle, n Z 43)
and CRF01_AE (open circle, n Z 18); (C) sDcR3 of HIV-1 pa-
tients belonged to fast progressors (open circle, n Z 23),
typical progressors (gray circle, n Z 25) and slow progressors
(black circle, nZ 13). The square represents the percentage of
detectable serum samples. The dash line indicates the median
of sDcR3. The p value was determined by Mann-Whitney Rank
Sum Test or Kruskal-Wallis One Way Test. *p < 0.05.
Decoy receptor 3 in sera of HIV-1 patients 501majority of the male patients with HIV-1/AIDS were infec-
ted with subtype B [39/50 (78.0%)]; in contrast, almost the
female patients were infected with CRF01_AE [7/11
(63.6%)] (Fisher’s exact test, p Z 0.011). A larger per-
centage of male than female patients belonged to fast
disease progressors (42.0% vs. 18.2%), while almost half of
the female patients belonged to typical disease progressors
(c2 test, p Z 0.32). We observed that virus-associated
factors were significantly different in sex between HIV-1-
infected patients (MWW Test, p Z 0.001 for CD4 counts;
pZ 0.007 for CD8 counts; and pZ 0.036 for viral load), as
well as some physiological values (MWW Test, p < 0.001 for
systolic pressure, diastolic pressure, GOT, and GPT). GOT
and GPT levels in the normal population were significantly
lower than that in HIV-1-infected patients (Mann-Whitney
Rank Sum Test, p < 0.001).
Comparison of serologic DcR3 concentrations in
HIV-1-infected patients
In total, the majority of 145 normal controls did not have
detectable sDcR3 (81% for male and 91% for female). Among
686 serum samples from 61 HIV-1-infected patients,
the sDcR3 concentration (median Z 0 ng/mL,
rangeZ 0e226 ng/mL) was significantly higher than that in
samples from the normal population (MWW Test, p < 0.001)
(Fig. 1A). Among HIV-1-infected patients, the sDcR3 level in
patients infected with subtype B (n Z 494 belong to 43
patients; median Z 2 ng/mL, range Z 0e226 ng/mL) was
significantly higher than that in patients infected with
CRF01_AE (n Z 192 belong to 18 patients; median Z 0 ng/
mL, range Z 0e65.1 ng/mL) (MWW Test, p < 0.001). In
addition, the sDcR3 in the majority of serum samples from
patients infected with CRF01_AE were under the detection
limit of the assay (43.5% for subtype B and 78.1% for
CRF01_AE). Because the patients in this study did not have
equal or consistent follow-ups, the follow-up period was
divided into seven 1-year time periods postdiagnosis for
analysis. As shown in Fig. 1B, after the day of diagnosis, the
sDcR3 in each year in patients infected with subtype B was
significantly higher than that in patients infected with
CRF01_AE. After the day of diagnosis, the sDcR3 in in-
dividuals with slow progression was higher than that in
those with fast and typical progression after 5 years post-
diagnosis (Kruskal-Wallis One Way Test, p Z 0.07 for 5
years, p Z 0.02 for 6 years, and p Z 0.003 for >6 years
postdiagnosis). The detected rates of serum samples in
patients with slow and typical progression increased grad-
ually (slope Z 9.42 for slow progressors, slope Z 5.63 for
typical progressors, and slope Z e1.4 for fast progressors)
(Fig. 1C).
Relationship between sDcR3 of HIV-1-infected
patients and clinical parameters
Repeated measurements of sDcR3 were analyzed using a
linear mixed regression model, accounting for the intra-
patient correlation related to AIDS disease progressors over
time. To assess the influence of sDcR3 in the HIV-1 patients,
we considered the virus-associated factors (i.e., subtypes,
viral load, CD4 and CD8 T cell counts) and physiologicalvalues (i.e., body temperature, WBC, lymphocyte counts,
RBC, systolic pressure, diastolic pressure, GOT, and GPT)
over time. In univariate analysis, significantly higher sDcR3
levels were observed in HIV-1 patients with subtype B (B vs.
CRF01_AE, pZ 0.0002), and slow disease progressors (slow
vs. typical progressors, p Z 0.0271; slow vs. fast
Table 2 Multivariate analysis of sDcR3 of HIV-1-infected patients by mixed model.
Variable Parameter estimate Standard error Mixed model, p
Intercept 13.4200 8.4617 0.1183
Times after diagnosis 0.4521 0.4254 0.2883
Age at diagnosis 0.1922 0.1742 0.2705
Sex (male vs. female) 12.2420 4.8689 0.0122
Subtype (B vs. CRF01_A/E) 13.0089 3.8607 0.0008
CD8 counts 0.0016 0.0022 0.4735
Disease progressions (slow vs. typical þ fast) 8.0102 3.9875 0.0450
502 Y.-T. Lin et al.progressors, pZ 0.0462) while adjusting sex and age (data
not shown). The results suggested that patients who
were infected with subtype B and belonged to the slow
progressors, had higher sDcR3 levels. In a multivariable
linear mixed model, variables were included which were
considered to be potentially influential to the concentra-
tion of sDcR3 or important confounding variables among
HIV-1 infected patients. A mixed model analysis demon-
strated that HIV-1 subtype and disease progression led to
higher levels of sDcR3 (beta Z 13.0089 and 8.0102;
p Z 0.0008 and 0.0450, respectively) (Table 2). The sDcR3
levels of slow progressors infected with subtype B were
significantly higher than those in the following three
groups: subtype B fast progressors (beta Z 10.1168,
p Z 0.0211), CRF01_AE slow progressors (beta Z 23.0200,
p Z 0.0159) and CRF01_AE fast progressors
(beta Z 21.3826, p < 0.0001).Discussion
In the previous study, researchers investigated the ampli-
fication and expression of DcR3 in the immune evasion of
EBV-associated lymphomas and HTLV-1-associated adult T
cell leukemia.20 DcR3 expression was also induced during
the early phase of Kaposi’s sarcoma-associated herpesvirus
(KSHV) infection.36 Ho et al demonstrated that EBV can
enhance DcR3 through its transcription activator.37 In the
present study, we analyzed the expression of DcR3, using
EIA, in HIV-1/AIDS patients and assessed the association of
sDcR3 and the disease progression of HIV-1 infection. Our
results demonstrate that higher levels of sDcR3 in HIV-1
patients infected with subtype B may slow down the rate
of disease progression. HIV-1 uses numerous mechanisms to
evade host immune responses, including impairment of HIV-
1 specific CD4 and CD8 T-cell function, downregulation of
HLA class I molecules, and mutations within defined CTL
epitopes.38e40 The strategies that not only prevent HIV-1
clearance, but also delay the progression to AIDS, in the
face of persistent immunity, are still not well understood. It
has been assumed that low immune activation found in
controllers and long-term nonprogressors, suggests that
immune activation forms an important role in the lack of
progression.41 Since TL1A can bind DR3 on immune cells,
where this interaction leads to activation and proliferation
of lymphocytes and NK cells, it has been speculated that
DcR3 might attenuate T-cell activation via its action as a
decoy receptor for TL1A.16 The immune-evasive and Th2-
promoting properties of DcR3, might confer benefits toslow down the rate of disease progression by dampening T-
cell activation.42 However, the detailed mechanism of DcR3
contributing to nonprogressors is still to be evaluated. It is
possible that HIV-1 uses DcR3 to escape the immune system
and confer survival advantage and delay disease progres-
sion. This is the first study investigating a possible rela-
tionship between sDcR3 and virus-associated factors of
patients infected with HIV-1. However, whether an HIV-1
gene regulates DcR3 expression and the role that DcR3
plays in the pathogenesis of HIV-1 infection needs to be
elucidated in further studies. In sum, HIV-1-infected cells
may gain a survival advantage by activating an immuno-
modulatory factor, DcR3, which prevents infected cell
detection by the host immune system. Further studies to
assess the usefulness of serologic DcR3 levels as a
biomarker in HIV-1 disease progression will be undertaken.Acknowledgments
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